SANTA CLARA, Calif.,
April 7, 2011 /PRNewswire/ -- PR
Newswire – NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic
technology provider, announced today that the Company has been
invited by the American Diabetes Association (ADA) to present the
results of a key study showing that NewCardio's urgent care
solution, my3KG™, had substantially greater accuracy than expert
cardiologists' interpretation of standard 12-lead ECG (12L ECG) in
diagnosing Acute Myocardial Infarction (AMI) in diabetic patients.
The presentation will be made at the 71st Annual ADA
Scientific Sessions to be held in San
Diego, CA, June 24-28, 2011.
In addition, the ADA has selected this presentation to be
showcased in the Guided Audio Poster Tour, which features expert
moderators that share their perspectives with attendees,
highlighting novel and important developments in the field.
Dr. Ihor Gussak, MD, PhD,
NewCardio's Chief Medical Officer, commented, "We are delighted to
present our study results at this important gathering of diabetes
experts, and particularly pleased that the ADA program committee
chose to feature our presentation in a moderated poster session.
Accurate and timely AMI diagnosis is a matter of great
concern for diabetologists, and we believe our results show that
my3KG can play a major role in solving it. The moderated
poster session provides the opportunity to present our results
directly to leading diabetes experts, and have one-on-one
interactions that will allow us to discuss and explain the
importance of our results in detail."
Study Background and Results
Diabetics with AMI represent a very large and growing patient
group, and currently affect over 10% of adults in the U.S.
Moreover, the incidence of AMI is two to four times greater
in diabetics than in the general population, according to ADA and
American Heart Association statistics. Accurate and timely
diagnosis of AMI is notoriously difficult in diabetics, largely
because the standard 12L ECG is often inaccurate, inconclusive or
non-diagnostic in this patient group. To address this
problem, investigators at the University of
Kansas Medical Center, in collaboration with NewCardio
physician-scientists, obtained detailed clinical and 12L ECG data
on 155 consecutive diabetic patients with suspected AMI, and
evaluated the diagnostic performance of my3KG in this patient
group.
The study showed that my3KG had 42% greater sensitivity than
expert cardiologist interpretation of 12L ECG for early detection
of AMI, with equal or better specificity. Based on these
important results, NewCardio believes use of my3KG in this patient
group may facilitate more accurate and timely diagnosis of AMI in
diabetic patients, thereby improving clinical outcomes.
NewCardio's innovative 3-D ECG platform technology dramatically
improves the accuracy and significantly increases the diagnostic
value of the standard 12L ECG. NewCardio is developing the
my3KG solution for urgent diagnosis of serious cardiac conditions,
including AMI. In clinical studies to date, the my3KG has
shown substantially improved diagnostic accuracy relative to the
standard 12L ECG, particularly in the most diagnostically
challenging patients (such as those with diabetes and electrical
conduction abnormalities). Accordingly, the Company believes
that its innovative my3kg solution will substantially improve
diagnostic timing and accuracy in life-threatening cardiac
conditions, and will thereby improve clinical outcomes for a broad
range of cardiac patients. The my3KG is not currently
marketed for sale in the U.S. The Company intends to file an
application for 510(k) approval with the FDA in 2011/2012.
About the American Diabetes Association
The ADA is a volunteer-driven organization based in Alexandria, VA, with affiliate offices across
the U.S. The mission of the ADA is to prevent and cure
diabetes and to improve the lives of all people affected by
diabetes. To fulfill this mission, the Association funds
research, publishes scientific findings, provides information and
other services to people with diabetes, their families, health
professionals and the public. The Association is also
actively involved in advocating for scientific research and for the
rights of people with diabetes. The Association acts on its
mission through a number of critical programs and activities that
are directed to a broad range of constituents, including consumers,
research scientists, health care professionals, corporations and
communities.
.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company
developing and marketing proprietary software platform technologies
to provide higher accuracy to, and increase the value of, the
standard 12L ECG. NewCardio's 3-D ECG software platform
reduces the time and expense involved in assessing cardiac status
while increasing the ability to diagnose clinically significant
conditions which were previously difficult to detect.
NewCardio's software products and services significantly
improve the diagnosis and monitoring of cardiovascular disease, as
well as cardiac safety assessment of drugs under development.
For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include, but are not limited to,
statements that express our intentions, beliefs, expectations,
strategies, predictions or any other statements relating to our
future activities or other future events or conditions. These
statements are based on current expectations, estimates and
projections about our business based on currently available
information and assumptions made by management. Although we
believe that the assumptions on which the forward-looking
statements contained herein are based are reasonable, any of those
assumptions could prove to be inaccurate given the inherent
uncertainties as to the occurrence or nonoccurrence of future
events. These statements are not guarantees of future
performance and involve risks and uncertainties that are difficult
to predict. Therefore, actual outcomes and results may, and
are likely to, differ materially from what is expressed or
forecasted in the forward-looking statements due to numerous
factors, including the potential risks and uncertainties set forth
in Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2010 and relate to our
business plan, our business strategy, development of our
proprietary technology platform and our products, timing of such
development, timing and results of clinical trials, level and
timing of FDA regulatory clearance or review, market acceptance of
our products, protection of our intellectual property,
implementation of our strategic, operating and people initiatives,
benefits to be derived from personnel and directors, ability to
commercialize our products, our assumptions regarding cash flow
from operations and cash on-hand, the amount and timing of
operating costs and capital expenditures relating to the expansion
of our business, operations and infrastructure, implementation of
marketing programs, our key agreements and strategic alliances, our
ability to obtain additional capital as, and when, needed, and on
acceptable terms and general economic conditions specific to our
industry, any of which could impact sales, costs and expenses
and/or planned strategies and timing. We assume no obligation
to, and do not currently intend to, update these forward-looking
statements.
To join our email distribution please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
